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Abstract
Background: Patients with advanced HIV infection at the time of diagnosis and patients not
responding to antiretroviral therapy are at risk of cytomegalovirus (CMV) disease. Earlier studies
of patients with HIV infection have demonstrated that the diagnosis is often first made post-
mortem. In recent years new molecular biological tests have become available for diagnosis of CMV
disease. Although clinical evaluation of tests for diagnosis of CMV disease in HIV-infected individuals
is suboptimal without autopsy, no results from such studies have been published. The aim of this
study was to explore the diagnostic utility of CMV quantitative polymerase chain reaction (PCR) in
plasma from HIV and CMV seropositive patients who died during the period 1991–2002 and in
whom autopsy was performed.
Methods: Autopsy was performed in all cases, as part of routine evaluation of HIV-infected cases
followed at Ullevaal University Hospital. Of 125 patients included, 53 had CMV disease, 37 of whom
were first diagnosed at autopsy. CMV disease was diagnosed either by ophthalmoscopic findings
typical of CMV retinitis, biopsy or autopsy. One or two plasma samples taken prior to the first
diagnosis of CMV disease (alive or at autopsy) or death without CMV disease were analysed by
CMV quantitative PCR. Sensitivity, specificity, positive and negative predictive values were
calculated for different CMV viral load cut-offs and according to detection of viraemia in one versus
two samples.
Results: Twenty-seven of 53 patients with CMV disease (51%) and 10 of 72 patients without CMV
disease (14%) had detectable viraemia in at least one sample. Sensitivity and negative predictive
value (NPV) of the test, maximised with a cut-off at the test's limit of detection of CMV viraemia
(400 copies/mL), were 47% and 70%, respectively. With cut-off at 10 000 copies/mL, specificity and
positive predictive value (PPV) were 100%. With a requirement for CMV viraemia in two samples,
specificity and PPV were 100% in patients with CMV viraemia above the limit of detection.
Conclusion: Our results indicate that quantitative CMV PCR is best used to rule in, rather than
to rule out CMV disease in HIV-infected individuals at high risk.
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Background
Although the incidence of cytomegalovirus (CMV) disease
in HIV-infected patients has declined sharply after the
introduction of highly active antiretroviral therapy
(HAART) [1], many patients are still at risk of CMV disease
[2,3]. Clinical features associated with CMV disease are,
with the exception of CMV retinitis, unspecific. In cases
with extra-ocular disease, histopathological findings typi-
cal of CMV are required for verification of the diagnosis.
Earlier studies, not using modern molecular biological
methods for CMV disease, demonstrated that CMV dis-
ease was under-diagnosed in HIV-infected patients, and
that the diagnosis was often first made at autopsy [4-10].
Newer diagnostic tests may improve the detection rate of
CMV disease in this patient population. French guidelines
recommend both ophthalmocsopy and testing for CMV
viraemia by PCR every three months in patients with CD
4 cell counts below 50–100/mm3, whereas U.S. guidelines
focus on the early clinical recognition of CMV disease
[11,12].
A variety of microbiological tests for detection of CMV
DNA in blood [3,13-27] and cerebrospinal fluid [28] have
been used in the diagnosis of CMV disease. Previous stud-
ies have demonstrated that detection of CMV DNA in
blood by PCR is a risk factor for subsequent development
of CMV disease. Sensitivity, specificity, positive and nega-
tive predictive value of these tests have shown great varia-
tion [13,18-20,23,26,27]. In one recent study, plasma
CMV viraemia was not found to be associated with later
development of CMV disease, but was predictive of death
[29].
Because diagnosis of CMV disease is often first made at
autopsy, sensitivity and negative predictive value of diag-
nostic tests may be overestimated, and specificity and pos-
itive predictive value may be underestimated if autopsy
results are not available. Furthermore, by using a quanti-
tative method it may be possible to improve specificity
and positive predictive value of CMV detection. However,
to our knowledge, no previous studies have related the
results of CMV quantitative PCR to autopsy findings. The
objective of this study was to explore the diagnostic utility
of CMV quantitative PCR in plasma samples from a group
of HIV infected patients who died during the study period
and in whom autopsy was performed.
Methods
Patients included in this retrospective study were HIV and
CMV seropositive adolescents and adults who died during
the period 1991–2002 while they were followed up at Ull-
evaal University Hospital. A total of 125 patients were
included. Patients were generally not screened for CMV
disease, even with low CD 4 cell counts, but fundoscopy
or biopsy of relevant organs was performed on the basis
of suggestive clinical signs and symptoms. Autopsy was
performed in all cases as part of routine practice in the
evaluation of HIV-infected cases who died at Ullevaal
University Hospital, unless this was objected to by rela-
tives. Patient characteristics are shown in Table 1.
A full autopsy including neuropathological examination
was performed in every case. Paraffin-embedded sections
were routinely stained with haematoxylin-eosin (HE),
and confirmatory immunohistochemistry for CMV was
performed in cases where microscopy of HE stained biop-
sies were inconclusive. CMV disease was verified by dem-
onstration of characteristic cytomegalocytes with
inclusions in histopathological samples by light micros-
copy. However, ante-mortem diagnosis of CMV retinitis
was defined as typical ophthalmoscopic findings in
patients examined by an experienced ophthalmologist.
Among 53 patients diagnosed with CMV disease, sixteen
patients were first diagnosed before death. Of patients
diagnosed alive, twelve had retinitis and four had biopsy
verified gastrointestinal infection (colitis 2, oesophagitis
1, stomatitis 1) as their first end-organ manifestation of
CMV disease. Except for two patients diagnosed with
retinitis alive, all had CMV disease confirmed in one or
several organs at autopsy. Thirty-seven cases were first
diagnosed at autopsy. In these patients the number of
CMV end-organ manifestations at autopsy were: adrenali-
tis 26, pneumonitis 22, encephalitis 16, retinitis 14, gas-
trointestinal infection 14 (oesphagitis 11, gastritis 1, small
intestine infection 1, colitis 1), and other end-organ dis-
ease 11 (prostate gland 5, ovaries 2, uterus 1, epididymis
1, lymph node 2, pancreas 5, spleen 3, liver 3, kidney 4,
myocardium 1, thyroid gland 4, vascular endothelium 1).
Twenty-patients first diagnosed at autopsy had more than
one organ manifestations of CMV disease.
Only twenty-eight patients received HAART at the time of
the last plasma sample tested for CMV DNA, either before
the first diagnosis of CMV disease (alive or at autopsy), or
before death in patients never developing CMV disease.
This is because the majority of plasma samples were taken
prior to the introduction of HAART in 1996. Seven cases
with CMV disease (diagnosed 1997–2002) were on
HAART when the last plasma sample was taken and later
analysed with CMV PCR. However, HIV viral load was
high in all, ranging from 17000 – >750 000 copies/mL.
Two of these seven cases had CMV retinitis diagnosed
alive, whereas the remaining five were first diagnosed with
CMV at autopsy.
Plasma aliquots were routinely collected and stored at -
20°C or colder during the study period, as part of clinical
follow-up of patients. From cases with CMV disease, theBMC Infectious Diseases 2007, 7:127 http://www.biomedcentral.com/1471-2334/7/127
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last one or two (according to availability) plasma samples
prior to diagnosis were retrospectively analysed by quan-
titative CMV PCR. In patients with more than one CMV
diagnosis at different time points during life or at autopsy,
plasma samples taken prior to the first CMV diagnosis
were tested. Similarly, for patients without CMV disease,
the last one or two plasma samples before death were
tested. The samples were analysed by COBAS AMPLICOR
CMV Monitor test (Roche Molecular System, Branchburg,
NJ) according to the manufacturer's recommendations.
One low-positive control, one high-positive control, and
one CMV-negative control were processed with each batch
of samples. The linear range of this assay is between 400
and 100 000 CMV DNA copies/mL plasma.
A total of 82 plasma samples were tested before diagnosis
in patients with CMV disease, and 127 samples were ana-
lysed from patients without CMV disease. Median time
interval between the last plasma sample and the date of
the first (or only) CMV diagnosis (alive or post-mortem)
was 69 days. Median time interval between the last
plasma sample and date of death in patients not develop-
ing CMV disease at any time was 79 days. This difference
was not statistically significant. For patients first diag-
nosed alive with CMV disease, the median time interval
between the last sample and diagnosis was 64 days, as
compared to 70 days for patients first diagnosed at
autopsy (statistically not significantly different). Among
29 patients with CMV disease and 55 patients without
CMV disease from whom two samples were tested,
median time intervals between the two tests were 77 days
and 90 days, respectively, again not statistically different.
The CMV quantitative PCR results were used to study sen-
sitivity, specificity, PPV and NPV of the test with different
cut-off values for CMV viral load, and with viraemia in
one versus two samples.
CD 4 cell counts were available from electronic records
and had been measured in blood samples taken on the
same day that plasma had been taken for later quantita-
tive CMV PCR.
SPSS statistical software version 13.0 (SPSS Inc. New York,
2004) was used to calculate Spearman rank correlation
between CD4 cell counts and CMV viral load. Statistical
differences between groups were calculated using non-
parametric tests (Mann-Whitney and chi-square test as
Table 1: Characteristics of 125 patients included in the study
Characteristic Value
CMV disease Without CMV disease
N = 53 (%) N = 72 (%)
Risk category
Men who have sex with men 32/53 (60) 30/72 (42)
Intravenous drug user 9/53 (17) 30/72 (42)
Other 10/53 (19) 11/72 (15)
Unknown 2/53 (4) 1/72 (1)
Age (median) at time of death, years 39 41
Sex
Male 46/53 (87) 58/72 (81)
Female 7/53 (13) 14/72 (19)
CD4 cell count*
Median count, cells/mm3 17 69
<100 cells/mm3 47/53 (89) 41/72 (57)
<50 cells/mm3 43/53 (81) 32/72 (44)
Highly active antiretroviral therapy* 7/53 (13) 21/72 (29)
Plasma HIV RNA level*
Tested 10/53 (19) 35/72 (49)
Median among tested, copies/mL blood 305 000 35 000
HIV RNA < 400 copies/mL blood 0/10 (0) 10/35 (29)
HIV RNA < 50 copies/mL blood 0/10 (0) 5/35 (14)
Data shown are number of subjects per no. of subjects with available data
* at time of last sample prior to diagnosis of CMV disease or death without CMV diseaseBMC Infectious Diseases 2007, 7:127 http://www.biomedcentral.com/1471-2334/7/127
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appropriate). Logistic regression was performed using
presence or absence of CMV disease as dependent variable
and last CD4 cell count (above or below 100/mm3, last
CMV viral load (log transformed), HAART (yes or no),
time in days between last plasma sample or outcome
defined as CMV disease or death without CMV disease,
sex, and age at time of death as independent variables.
Confidence Interval Analysis statistical software (Wilson's
method) was used to calculate sensitivity, specificity, PPV
and NPV with confidence intervals. All confidence inter-
vals (CI) are 95% CIs. The significance level was set at 5%.
Results
Twenty-seven of 53 patients with CMV disease (51%) and
10 of 72 patients without CMV disease (13%) had detect-
able viraemia in at least one sample (p < 0.001). Results
of CMV quantitative PCR from the last plasma sample are
shown in Table 2. There was significantly higher CMV
viral load in patients with CMV disease compared to
patients without CMV disease (p < 0.001). In 25 patients
with CMV disease and 8 patients without CMV disease
who had viraemia in the last sample, median CMV viral
loads were 3420 (range 392–261 000) and 1705 (range
277–9620) DNA copies/mL, respectively (statistically not
significantly different). Table 2 also shows the number of
cases with detectable CMV viraemia according to the
number of samples tested.
Among 16 patients diagnosed alive with CMV disease, 7
(44%) had detectable CMV viraemia in the last sample
before diagnosis (median 1810 DNA copies/mL among
viraemic cases). Among 37 patients first diagnosed with
CMV disease at autopsy, 18 (49%) had CMV viraemia in
the last sample (median 4430 DNA copies/mL among
viraemic cases). There was no significant difference in the
proportion of cases with viraemia (sensitivity) or level of
viraemia between these two groups of patients.
In 37 patients first diagnosed with CMV disease at
autopsy, 14 of 20 patients with CMV disease in more than
one organ had detectable CMV viremia in the last sample
(median 7035 copies/mL among viraemic cases), com-
pared to 4 of 17 patients with CMV disease in a single
organ, (median 2680 DNA copies/mL among viraemic
cases). In other words, sensitivity of the test was 70% for
cases with multi-organ disease and 24% for cases with sin-
gle organ disease (p = 0.005). However, among viraemic
cases there was no statistically significant difference in
CMV viral load.
Results from Table 2 were used to calculate the corre-
sponding sensitivity, specificity, PPV and NPV with
increasing CMV viral load cut-off, and with one or two
samples with detectable viraemia in individual patients
(Table 3). The viral load cut-off is defined as the lowest
level of viraemia which is considered a positive result for
diagnostic purposes. Sensitivity and NPV were generally
low under a wide range of assumptions. Specificity and
PPV were generally higher, and were improved further by
raising the viral load cut-off. By setting the cut-off at 10
000 CMV DNA copies/mL plasma, a specificity of 100%
was attained, but at the expense of sensitivity which fell to
17%. Also, a specificity and PPV of 100% was achieved by
defining a positive test as CMV viraemia in two samples.
The proportion of cases with CMV disease that have a pos-
itive tests (sensitivity) plotted against the proportion of
cases without CMV disease that have a positive test (1-spe-
cificity) for all measured values of CMV DNA viraemia in
the last plasma sample are shown as a receiver operating
characteristic (ROC) curve in Figure 1. Using the lowest
detectable level of viraemia as cut-off, a maximum sensi-
tivity of 47.2% was attained. However, specificity of 1
(100%) (1-specifity = 0) was attained with a cut-off of 10
000 CMV DNA copies/mL as mentioned above. The diag-
nostic accuracy of the test, expressed by the area under the
curve, was 0.69. This area corresponds to the probability
that a random person with the disease has a higher CMV
viral load than a random person without CMV disease.
CMV viraemia was negatively correlated with CD4 cell
counts (rS = -0.24 (p < 0.01). In the multivariable logistic
regression model low CD4 cell counts and high CMV viral
load were the only statistically significant positive predic-
tors of CMV disease.
Discussion
With the exception of retinitis, end-organ manifestations
of CMV disease in HIV-infected individuals have unspe-
cific clinical characteristics, and histopathological confir-
mation is required for definite diagnosis. Because biopsy
of affected organs may be difficult to obtain, there is a
need for microbiological diagnostic methods that can be
used on readily available specimens. A variety of tests to
detect CMV nucleic acids have been evaluated in different
patient populations. To our knowledge, no previous tests
have been evaluated in relation to autopsy findings, an
important shortcoming, as histological verification of
CMV disease is often first obtained at autopsy. The main
strength of this study is that it explores the utility of quan-
titative PCR in the diagnosis of CMV disease in HIV-
infected individuals with available autopsy results. Also, it
includes one of the highest reported number of cases of
CMV disease in HIV-infected patients evaluated with CMV
PCR.
Several qualitative and quantitative PCR methods for
CMV in plasma in various patient populations have dem-
onstrated sensitivity in the range 35–93% [13,18-
20,23,26,27]. In our study, maximum sensitivity of 47%BMC Infectious Diseases 2007, 7:127 http://www.biomedcentral.com/1471-2334/7/127
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for the total number of cases, using a cut-off at the limit of
detection, was in the lower end of this range. In a small
previous study on HIV-infected individuals using COBAS
AMPLICOR CMV Monitor, sensitivity was 92% [27]. The
relatively low sensitivity in our study could be due to sam-
ples in many cases having been taken as part of routine
monitoring and therefore too long, a median of 69 days,
before development of CMV end-organ disease. However,
CMV viraemia is known to often precede development of
CMV disease by several months [2,13,17]. Also, in con-
trast to previous studies, most of our cases of CMV disease
were first diagnosed at autopsy, and it is possible that
these post-mortem manifestations are associated with a
shorter time with viraemia and/or lower level of viraemia.
Interestingly, our results show that sensitivity was signifi-
cantly higher for patients with CMV disease in more than
one organ compared to patients with single organ disease.
Previous studies of CMV disease diagnosed before death
have yielded specificities in the range 47–100% [13,18-
20,23,26,27]. Our study shows specificity in the upper
range (89%), with only 8 of 72 (11%) cases having detect-
able CMV viraemia but no diagnosis of CMV disease (false
positive tests). Studies that do not include autopsy results
may underestimate the specificity, as CMV end-organ dis-
ease may be a difficult clinical diagnose to make.
Our data were also analysed with regard to detection of
CMV viraemia in one versus two plasma samples taken at
different times. We found that cases with detectable CMV
viraemia in both samples all developed CMV disease.
Thus, by requiring confirmation in a second test if the first
was positive, a specificity of 100% was attained, but at the
cost of lower sensitivity.
From a clinician's point of view, the predictive value of a
positive and negative test result has greater practical impli-
cations than do sensitivity and specificity. The predictive
value of any test is generally dependent on the prevalence
of the disease in question in the study population, NPV
decreasing and PPV increasing with increasing prevalence.
Previous studies have reported NPV in the range 80–95%
[20,23,26,27], which is somewhat higher than in our
study. The prevalence of CMV disease in our study was
comparatively high – 42% (53 of 125 patients) – thus
contributing to a low NPV. For the same reason, the PPV
demonstrated in our study was among the highest
reported. In our patient population at high risk of CMV
disease we attained a PPV of 100% with a cut off-value of
10 000 CMV DNA copies/mL or a requirement for virae-
mia in two consecutive tests. Studies that do not include
autopsy results may underestimate the proportion of cases
with CMV disease, resulting in an overestimation of the
NPV and an underestimation of the PPV.
The study covers a period both before and after HAART
became standard of care. Even in patients on HAART,
antiretroviral treatment was suboptimal for many, proba-
bly due to HIV resistance having developed after previous
ineffective therapy with single drugs, or combination of
two antiretrovirals. This may affect the external validity of
our results in the diagnosis of CMV disease in HIV-
Table 2: Results of CMV quantitative PCR in patients with and without CMV disease
Results of CMV PCR assay Number of patients
with CMV disease without CMV disease
N = 53 N = 72
Viral load (CMV DNA copies/mL) (last samples)
Below limit of detection 28 64
Viraemiaa 25 8
≤1 999 95
2 000–9 999 73
≥10 000 90
CMV DNA detectiona by no. of tested samples before diagnosis
One sample 24 17
Not detected in any sample 13 15
Detected in one sample 11 2
Two samples 29 55
Not detected in any sample 13 47
Detected in one sample 9 8
Detected in both samples 7 0
aAny viraemia above limit of detection.
Results of plasma CMV quantitative PCR in HIV patients with and without CMV disease by different viral load cut-offs and number of tested 
samples.BMC Infectious Diseases 2007, 7:127 http://www.biomedcentral.com/1471-2334/7/127
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infected patients who have access to more effective
HAART today and, as a result, have lower risk of CMV dis-
ease. However, results from our study are likely to be rele-
vant for patients who interrupt treatment, who fail to
respond to antiretroviral therapy, or who are diagnosed
too late for effective HIV therapy to be initiated.
This was a retrospective study in which the time intervals
varied considerably between the last plasma sample and
CMV diagnosis (alive or at autopsy), or between the last
plasma sample and death in cases without CMV disease,
as samples were taken as part of routine monitoring of the
patients rather than on clinical suspicion. It is likely that
the sensitivity and PPV of CMV PCR will be higher in a set-
ting where plasma is analysed at a time of clinical suspi-
cion of CMV end-organ disease, rather than as part of
routine monitoring of patients.
The availability of more than one plasma sample from
individual patients at relevant time points was limited,
but a high positive predictive value for CMV disease was
found for patients with CMV viraemia in two consecutive
tests with a median time interval of between two and three
months. However, our data do not allow us to conclude
when plasma CMV quantitative PCR should be per-
formed, or how soon a patient should be retested after a
positive test result.
In solid organ transplant patients and allogenic bone mar-
row transplantation, routine monitoring of virological
markers for cytomegalovirus and administration of pre-
emptive therapy has been shown to significantly reduce
the risk of CMV disease [30,31], and post-transplant mon-
itoring of CMV viraemia by PCR or other methods is used
in many centres. Among HIV-infected individuals the
value of pre-emptive therapy is less well documented, but
monitoring of high risk patients for this purpose is recom-
mended in French guidelines [11].
Many studies have shown that the risk of CMV disease
sharply increases when CD4 cell counts fall below 100/
mm3 [2,3,32]. We suggest that HIV infected patients with
low CD4 cell counts who have clinical features suggestive
of CMV disease, should have plasma tested for CMV by
quantitative PCR as part of the diagnostic procedure. In
patients with repeated viraemia or viraemia above 10 000
CMV DNA copies/mL, pre-emptive therapy should be
considered after a careful clinical examination for signs
and symptoms of CMV end-organ disease. However, our
findings need to be validated in prospective studies on
patients living with HIV today.
Conclusion
Using CMV quantitative PCR, the sensitivity and NPV for
CMV disease were low in this study. Our results indicate
that in a population at high risk of CMV disease quantita-
tive CMV PCR is best used to rule in, rather than to rule
out CMV disease. Although CMV disease presently is rela-
tively uncommon in HIV-infected patients who have
access to antiretroviral therapy, these results may have
implications for diagnosis of CMV disease in patients with
low CD4 cell counts due to late HIV diagnosis or failure of
antiretroviral therapy.
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